Savara (SVRA) Competitors

$3.65

-0.01 (-0.27%)

(As of 10/15/2024 ET)

SVRA vs. KMPH, GLSI, PPBT, STSA, SYBX, HRMY, GLPG, KNSA, MIRM, and LGND

Should you be buying Savara stock or one of its competitors? The main competitors of Savara include Zevra Therapeutics (KMPH), Greenwich LifeSciences (GLSI), Purple Biotech (PPBT), Satsuma Pharmaceuticals (STSA), Synlogic (SYBX), Harmony Biosciences (HRMY), Galapagos (GLPG), Kiniksa Pharmaceuticals (KNSA), Mirum Pharmaceuticals (MIRM), and Ligand Pharmaceuticals (LGND). These companies are all part of the "pharmaceutical preparations" industry.

Savara vs.

Zevra Therapeutics (NASDAQ:KMPH) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, community ranking, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

: In the previous week, Savara had 5 more articles in the media than Zevra Therapeutics. MarketBeat recorded 5 mentions for Savara and 0 mentions for Zevra Therapeutics. Savara's average media sentiment score of 0.49 beat Zevra Therapeutics' score of 0.00 indicating that Savara is being referred to more favorably in the news media.
Company Overall Sentiment
Zevra Therapeutics Neutral
Savara Neutral
: 19.4% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 1.1% of Zevra Therapeutics shares are held by insiders. Comparatively, 5.1% of Savara shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: Savara has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -328.56%. Zevra Therapeutics' return on equity of -16.12% beat Savara's return on equity.
Company Net Margins Return on Equity Return on Assets
Zevra Therapeutics -328.56% -16.12% -14.17%
Savara N/A -58.99% -45.79%
: Zevra Therapeutics received 48 more outperform votes than Savara when rated by MarketBeat users. However, 66.74% of users gave Savara an outperform vote while only 61.17% of users gave Zevra Therapeutics an outperform vote.
Company Underperform Outperform
Zevra Therapeutics Outperform Votes
345
61.17%
Underperform Votes
219
38.83%
Savara Outperform Votes
297
66.74%
Underperform Votes
148
33.26%
: Zevra Therapeutics has higher revenue and earnings than Savara.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zevra Therapeutics $10.72M 0.00 -$8.56M N/A N/A
Savara N/A N/A -$54.70M -$0.37 -9.86
: Savara has a consensus target price of $11.17, indicating a potential upside of 205.94%. Given Savara's higher possible upside, analysts plainly believe Savara is more favorable than Zevra Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zevra Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Savara
0 Sell rating(s)

0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
3.00
: Zevra Therapeutics has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.

Company	Overall Sentiment
Zevra Therapeutics	Neutral
Savara	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	-328.56%	-16.12%	-14.17%
Savara	N/A	-58.99%	-45.79%

Company	Underperform	Outperform
Zevra Therapeutics	Outperform Votes 345 61.17%	Underperform Votes 219 38.83%
Savara	Outperform Votes 297 66.74%	Underperform Votes 148 33.26%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$10.72M	0.00	-$8.56M	N/A	N/A
Savara	N/A	N/A	-$54.70M	-$0.37	-9.86

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Savara	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Savara beats Zevra Therapeutics on 8 of the 14 factors compared between the two stocks.

Ad Crypto Swap Profits

625,000% Gain

The recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull run is over. But if history has taught us anything, it’s that this is only the beginning.

>> Dive into the Workshop Here

Get Savara News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVRA vs. The Competition

Export to Excel

Metric	Savara	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$504.39M	$5.74B	$5.49B	$8.45B
Dividend Yield	N/A	9.68%	4.36%	4.14%
P/E Ratio	-8.69	21.95	129.82	19.48
Price / Sales	N/A	263.49	1,174.85	73.52
Price / Cash	N/A	48.26	38.28	33.49
Price / Book	3.51	5.60	4.72	4.60
Net Income	-$54.70M	$113.27M	$120.06M	$227.38M
7 Day Performance	N/A	2.54%	3.61%	3.07%
1 Month Performance	-15.51%	19.22%	15.68%	11.11%
1 Year Performance	3.99%	26.57%	30.06%	24.68%

Savara Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVRA Savara	1.9039 of 5 stars	$3.65 -0.3%	$11.17 +205.9%	+11.6%	$504.39M	N/A	-8.69	N/A
KMPH Zevra Therapeutics	N/A	N/A	N/A	N/A	$200.47M	$10.72M	0.00	22	Analyst Forecast
GLSI Greenwich LifeSciences	2.7201 of 5 stars	$13.79 +0.4%	$38.00 +175.6%	+63.9%	$177.62M	N/A	-17.46	3	Upcoming Earnings Positive News
PPBT Purple Biotech	3.254 of 5 stars	$4.10 -2.4%	$10.00 +143.9%	N/A	$103.48M	N/A	-0.32	20	Gap Down
STSA Satsuma Pharmaceuticals	1.0891 of 5 stars	$1.10 -0.9%	N/A	+0.0%	$36.47M	N/A	-0.55	21	High Trading Volume
SYBX Synlogic	3.0246 of 5 stars	$1.40 flat	$30.00 +2,042.9%	-41.4%	$16.39M	$3.17M	-0.21	80	Positive News Gap Up
HRMY Harmony Biosciences	3.7141 of 5 stars	$35.48 +1.9%	$44.11 +24.3%	+68.2%	$2.01B	$656.11M	18.19	200
GLPG Galapagos	0.2527 of 5 stars	$29.27 -1.8%	$31.00 +5.9%	-15.5%	$1.93B	$261.40M	0.00	1,123	Positive News
KNSA Kiniksa Pharmaceuticals	2.833 of 5 stars	$26.63 +0.3%	$33.60 +26.2%	+65.9%	$1.89B	$338.93M	-166.43	220	Short Interest ↓ Positive News
MIRM Mirum Pharmaceuticals	4.0384 of 5 stars	$39.77 -0.8%	$56.27 +41.5%	+41.2%	$1.87B	$264.38M	-17.37	140
LGND Ligand Pharmaceuticals	4.7326 of 5 stars	$103.46 +0.5%	$131.80 +27.4%	+89.8%	$1.86B	$133.48M	47.90	80	Positive News